FARA

Vesigen Therapeutics is a biotechnology company focused on delivering therapeutic payloads into intracellular targets using ARMMs (ARRDC1 Mediated Microvesicles) extracellular vesicle delivery technology. It designs and develops medicines that enable intracellular delivery and address barriers related to cell membranes and degradative systems, enabling a broad range of payloads to reach target cells. Its ARMMs platform supports delivery of RNA-based therapies, proteins, and gene-editing complexes such as Cas9/gRNA directly into the cytoplasm, expanding the universe of druggable targets and enabling new treatments for unmet medical needs. Vesigen Therapeutics aims to advance intracellular drug modalities to widen therapeutic possibilities across diseases. It was incorporated in 2020 and is based in Cambridge, Massachusetts.